


FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

M#

Client Ref.

0275470

1997-30-0565CP1

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: REFF *et al.*

Appln. No.: 09/019,441

Filing Date: February 5, 1998

Examiner: P. Huynh

Group Art Unit: 1644

Date: November 5, 2003

Page

1

of

3

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
PWH	AR 4,975,369	12/1990	Beavers <i>et al.</i>			
	BR 5,648,267	07/1997	Reff			
	CR 5,736,137	04/1998	Anderson			
	DR 5,811,524	09/1998	Brams <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
PWH	ER WO 89/00138	01/1989	WIPO	Gunnar Strömberg		
	FR WO 92/17707	10/1992	WIPO	Tanox Biosystems Inc.		
	GR WO 93/02108	02/1993	WIPO	IDEC Pharmaceuticals Inc.		
	HR WO 96/12742	05/1996	WIPO	Glaxo Group Ltd.		

## OTHER

PWH	IR	Luo <i>et al.</i> , "Cross-linking of CD23 antigen by its natural ligand (IgE) or by anti-CD23 antibody prevents B lymphocyte proliferation and differentiation", <i>J. Immunol.</i> , 146(7):2122-9 (1991).				
	JR	Groves <i>et al.</i> , "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion", <i>Hybridoma</i> , vol. 6(1):71 (1987).				
	KR	Robbins, <i>Pathologic Basis of Disease</i> , 5th Ed., ed. by Cotran <i>et al.</i> , W.B. Saunders Co., Philadelphia, PA, 1994, pp. 197-199.				
	LR	Seaver, <i>Genetic Engineering News</i> , 14(14): pp. 19, 21 (Aug., 1994).				
	MR	Haak-Frendscho <i>et al.</i> , "Administration of an anti-IgE antibody inhibits CD23 expression and IgE production <i>in vivo</i> ", <i>Immunology</i> , 82:306 (1994).				
	NR	Delespesse <i>et al.</i> , "Human IgE-binding factors", <i>Immunology Today</i> 10:159, (1989).				
	OR	Durum <i>et al.</i> , "Proinflammatory Cytokines and Immunity," in <i>Fundamental Immunology</i> , Third Edition, Chapter 21, ed. by Paul <i>et al.</i> , Raven Press, Ltd., New York, p. 826 (1993).				
	PR	Vercelli <i>et al.</i> , "Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens", <i>J. Exp. Med.</i> , 169:1295 (Apr. 1989).				
	QR	Presta <i>et al.</i> , "Humanization of an antibody directed against IgE", <i>J. Immunology</i> , 151(5):2623 (Sep. 1993).				
	RR	Strike <i>et al.</i> , "Production of human-human hybridomas secreting antibody to sheep erythrocytes after <i>in vitro</i> immunization", <i>J. Immunol.</i> , 132(4): 1798 (Apr. 1984).				
	SR	Cruse <i>et al.</i> , <i>Illustrated Dictionary of Immunology</i> , CRC Press, Boca Raton, Fla., 1995, p. 69.				
	TR	Capon <i>et al.</i> , "Designing CD4 immunoadhesins for AIDS therapy", <i>Nature</i> , 337:525 (Feb. 1989).				
	UR	Rector <i>et al.</i> , "Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry", <i>Immunol.</i> , 55: 481-488 (1985).				
	VR	Suemura <i>et al.</i> , "Monoclonal anti-Fc epsilon receptor antibodies with different specificities and studies on the expression of Fc epsilon receptors on human B and T cells", <i>J. Immunol.</i> , 137: 1214-1220 (1986).				
	WR	Noro <i>et al.</i> , "Monoclonal antibody (H107) inhibiting IgE binding to Fc epsilon R(+) human lymphocytes", <i>J. Immunol.</i> , 137: 1258-1263 (1986).				
	XR	Yu <i>et al.</i> , "Negative feedback regulation of IgE synthesis by murine CD23", <i>Nature</i> , 369: 753-756 (1994).				

*[Handwritten signature]*

1/5/03

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Date: November 5, 2003	Page 2 of 3	Applicant: REFF et al.	Appl. No.: 09/019,441
OTHER (Continued)		Client Ref. No.: 997-30-0565CP1	Atty. Dkt. No.: 037003-0275470	Examiner: P. Huynh	Group Art Unit: 1644
PNH	YR	Bonnefoy et al., "Regulation of IgE synthesis by CD23/CD21 interaction", Int. Arch. Allergy Immunol., 107: 40-42 (1995).			
	ZR	Aubry et al., "CD21 is a ligand for CD23 and regulates IgE production," Nature, 358:505-507 (1992).			
	AAR	Bonnefoy et al., "Receptors for IgE", Curr. Opin. Immunol., 5: 944-949 (1993).			
	BBR	Grosjean et al., "CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones", Eur. J. Immunol., 24: 2982-2988 (1994).			
	CCR	Pene et al., "Interleukin 5 enhances interleukin 4-induced IgE production by normal human B cells. The role of soluble CD23 antigen", Eur J. Immunol., 18: 929-935 (1988).			
	DDR	Saxon et al., "Soluble CD23 containing B cell supernatants induce IgE from peripheral blood B-lymphocytes and costimulate with interleukin-4 in induction of IgE", J. Allergy Clin. Immunol., 86 (3 pt 1) 333-344 (1990).			
	EER	Hassner and Saxon, "Isotype-specific human suppressor T cells for IgE synthesis activated by IgE-anti-IgE immune complexes", J. Immunol., 132: 2844 (1984).			
	FFR	Carroll et al., "Mouse x human heterohybridomas as fusion partners with human B cell tumors", J. Immunol. Methods 89: 61 (1986).			
	GGR	Boerner et al., "Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes", J. Immunol., 147: 86 (1991).			
	HHR	Bourget et al., "CD20 monoclonal antibodies decrease interleukin-4-stimulated expression of the low-affinity receptor for IgE (Fc epsilon RII/CD23) in human B cells by increasing the extent of its cleavage," Eur. J. Immunol., 25(7):1872-76 (1995).			
	IIR	Bonnefoy et al., "A new role for CD23 in inflammation", Immunol. Today, 17(9): 418-20 (1996).			
	JJR	Plater-Zyberk et al., "Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo" Nature Medicine, 1(8):781-785 (1995).			
	KKR	The Merck Manual, 16 <sup>th</sup> Edition, Berkow, R. ed., Rahway, NJ, pp. 1305-12 and 1334-8 (1992).			
	LLR	Busse et al., "Results of a Phase I, Single-dose, Dose-escalating Trial of a Primatized Anti-Cd23 Monoclonal Antibody (IDEC-152) in Patients With Allergic Asthma," J. of Allergy and Clinical Immunol., 107(2): abstract no. 354 (Feb. 2001).			
	MMR	Nakamura et al., "In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain", Intl. J. of Immunopharmacol., 22:131-41 (2000).			
	NNR	Bettler et al., "Binding site for IgE of the human lymphocyte low-affinity Fc epsilon receptor (Fc epsilon RII/CD23) is confined to the domain homologous with animal lectins", Proc. Natl. Acad. Sci., USA, 86:7118-22 (1989).			
	OOR	Webster's II New Riverside University Dictionary, Houghton-Mifflin Co., Boston, p. 933 (1984).			
	PPR	Yoshikawa et al., "Soluble Fc epsilon RII/CD23 in patients with autoimmune diseases and Epstein-Barr virus-related disorders: analysis by ELISA for soluble Fc epsilon RII/CD23", Immunomethods, 4(1):65-71 (Feb. 1994).			
	QQR	Muino et al., "The importance of specific IgG and IgE autoantibodies to retinal S antigen, total serum IgE, and sCD23 levels in autoimmune and infectious uveitis", J. Clin. Immunol., 19(4):215-222 (Jul. 1999).			
	RRR	Soh et al., "IgE and its related phenomena in bullous pemphigoid", Br. J. Dermatol., 128:371-377 (1993).			
	SSR	Fries et al., "Monocyte receptors for the Fc portion of IgG studies with monomeric human IgG1: normal in vitro expression of Fc gamma receptors in HLA-B8/Drw3 subjects with defective Fc gamma-mediated in vivo clearance", J. Immunol., 129: 1041-1049 (1982).			
	TTR	Kurlander and Batker et al., "The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes", J. Clin. Invest., 69: 1-8 (1982).			
	UUR	Woof, "The monocyte binding domain(s) on human immunoglobulin G", Mol. Immunol., 21:523-527 (1984).			
	VVR	Burton and Woof, "Human antibody effector function", Human Antibody Effector Function, Adv. Immunol., 51: 1-84 (1992).			
✓	WWR	Karas et al., "Characterization of the IgG-Fc receptor on human platelets", Blood, 60:1277-1282 (1982).			

*Handwritten signature*

*Handwritten signature*

NOV 06 2003

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Date: November 5, 2003	Page 3 of 3	Applicant: REFF et al.	Appln. No.: 09/019,441
OTHER (C ntinued)		Client Ref. No.: 1997-30-0565CP1	Atty. Dkt. No.: 037003-0275470	Examiner: P. Huynh	Group Art Unit: 1644
<input checked="" type="checkbox"/>	XXR	Van de Winkel and Anderson, "Biology of human immunoglobulin G Fc receptors", J. Leuk. Biol., 49:511-524 (1991).			
<input type="checkbox"/>	YYR	Huizinga et al., "Binding characteristics of dimeric IgG subclass complexes to human neutrophils", J. Immunol., 142:2359-2364 (1989).			
<input type="checkbox"/>	ZZR	Bosma et al., "A severe combined immunodeficiency mutation in the mouse", Nature, 301:527 (1983).			
<input type="checkbox"/>	AAAR	Mosier et al., "Transfer of a functional human immune system to mice with severe combined immunodeficiency", Nature, 335:256 (1988).			
<input type="checkbox"/>	BBBR	Mosier et al., "Immunodeficient mice xenografted with human lymphoid cells: new models for in vivo studies of human immunobiology and infectious diseases", J Clin Immunol., 10:185-91 (1990).			
<input type="checkbox"/>	CCCR	Abedi et al., "Immunoglobulin production in severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood mononuclear cells", Eur. J. Immunol., 22:823 (1992).			
<input type="checkbox"/>	DDDR	Mazingue et al., "Obtention of a human primary humoral response against schistosome protective antigens in severe combined immunodeficiency mice after the transfer of human peripheral blood mononuclear cells", Eur. J. Immunol., 21:1763 (1991).			
<input type="checkbox"/>	EEER	Kilchherr et al., "Regulation of human IgE response in hu-PBL-SCID mice", Cellular Immunology, 151:241 (1993).			
<input type="checkbox"/>	FFFR	Spiegelberg et al., "Role of interleukin-4 in human immunoglobulin E formation in hu-PBL-SCID mice", J. Clin. Invest., 93:711 (1994).			
<input type="checkbox"/>	GGGR	Carballido et al., "IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist", J. Immunol., 155:4162 (1995).			
<input type="checkbox"/>	HHHR	King et al., "Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment", Biochem. J., 281:317-23 (1992).			
<input type="checkbox"/>	IIIR	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor ", Proc. Nat. Acad. Sci. USA, 86:10029 (1989).			
<input type="checkbox"/>	JJJR	Love et al., "Recombinant antibodies possessing novel effector functions", Methods Enzymol., 178:515-27 (1989).			
<input type="checkbox"/>	KKKR	Hutzel et al., "Generation and characterization of a recombinant/chimeric B72.3 (human $\gamma_1$ )", Cancer Res., 51:181 (1991).			
<input type="checkbox"/>	LLLR	Chiang et al., "Direct cDNA cloning of the rearranged immunoglobulin variable region", Biotechniques, 7(4):360-6 (1989).			
<input type="checkbox"/>	MMMR	Heinrich et al., "Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions", J. Immunol., 143:3589 (1989).			
<input type="checkbox"/>	NNNR	Hardman et al., "Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen", Int. J. Cancer, 44:424 (1989).			
<input type="checkbox"/>	OOOR	Orlandi et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction", Proc. Nat. Acad. Sci. USA, 86(10):3833-7 (1989).			
<input type="checkbox"/>	PPPR	Norman et al., "Reversal of Acute Allograft Rejection With Monoclonal Antibody," Transpl. Proc., 17:39-41 (1985).			
<input type="checkbox"/>	QQQR	Sarfati et al., "Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia", Blood, 71:94-98 (1988).			
<input checked="" type="checkbox"/>	RRRR	Saragovi et al., "Design and synthesis of a mimetic from an antibody complementarity-determining region", Science, 16:253(5021):792-5.			
Examiner: <i>Phy N. [Signature]</i>			Date Considered: 1/5/04		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>					